Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
An oncolytic virus delivering tumor-irrelevant bystander T-cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy
Medical Classification: Class 3 Medicine Efficacy: pigmentation caused by dark spots, freckles, sun exposure, and others
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
For the wider research view, see the Cagrilintide guide on how it works, study results, side effects, and legal status
Yes, this combination is common
)
US$ 22.02
US$ 23.46
US$ 22.74
:max_bytes(150000):strip_icc()/GettyImages-2169095535-f8d8276415dd4300a867a1f8b7de098f.jpg)
US$ 20.33
